| Human epidermal growth factor receptor 2 (HER2)–specific chimeric antigen receptor–modified T cells for the immunotherapy of HER2-positive sarcoma N Ahmed, VS Brawley, M Hegde, C Robertson, A Ghazi, C Gerken, E Liu, ... Journal of clinical oncology 33 (15), 1688-1696, 2015 | 1022 | 2015 |
| HER2-specific chimeric antigen receptor–modified virus-specific T cells for progressive glioblastoma: a phase 1 dose-escalation trial N Ahmed, V Brawley, M Hegde, K Bielamowicz, M Kalra, D Landi, ... JAMA oncology 3 (8), 1094-1101, 2017 | 729 | 2017 |
| Design and development of therapies using chimeric antigen receptor‐expressing T cells G Dotti, S Gottschalk, B Savoldo, MK Brenner Immunological reviews 257 (1), 107-126, 2014 | 666 | 2014 |
| Tandem CAR T cells targeting HER2 and IL13Rα2 mitigate tumor antigen escape M Hegde, M Mukherjee, Z Grada, A Pignata, D Landi, SA Navai, ... The Journal of clinical investigation 126 (8), 3036-3052, 2016 | 648 | 2016 |
| Post-transplant lymphoproliferative disorders S Gottschalk, CM Rooney, HE Heslop Annu. Rev. Med. 56 (1), 29-44, 2005 | 552 | 2005 |
| Sustained complete responses in patients with lymphoma receiving autologous cytotoxic T lymphocytes targeting Epstein-Barr virus latent membrane proteins CM Bollard, S Gottschalk, V Torrano, O Diouf, S Ku, Y Hazrat, G Carrum, ... Journal of Clinical Oncology 32 (8), 798-808, 2014 | 528 | 2014 |
| TanCAR: a novel bispecific chimeric antigen receptor for cancer immunotherapy Z Grada, M Hegde, T Byrd, DR Shaffer, A Ghazi, VS Brawley, A Corder, ... Molecular Therapy-Nucleic Acids 2, 2013 | 520 | 2013 |
| Off-the-shelf virus-specific T cells to treat BK virus, human herpesvirus 6, cytomegalovirus, Epstein-Barr virus, and adenovirus infections after allogeneic hematopoietic stem … I Tzannou, A Papadopoulou, S Naik, K Leung, CA Martinez, CA Ramos, ... Journal of Clinical Oncology 35 (31), 3547-3557, 2017 | 428 | 2017 |
| A novel DNA-peptide complex for efficient gene transfer and expression in mammalian cells. S Gottschalk, JT Sparrow, J Hauer, MP Mims, FE Leland, SL Woo, ... Gene therapy 3 (5), 448-457, 1996 | 416 | 1996 |
| Combinational targeting offsets antigen escape and enhances effector functions of adoptively transferred T cells in glioblastoma M Hegde, A Corder, KKH Chow, M Mukherjee, A Ashoori, Y Kew, ... Molecular Therapy 21 (11), 2087-2101, 2013 | 402 | 2013 |
| HER2-specific T cells target primary glioblastoma stem cells and induce regression of autologous experimental tumors N Ahmed, VS Salsman, Y Kew, D Shaffer, S Powell, YJ Zhang, ... Clinical cancer research 16 (2), 474-485, 2010 | 402 | 2010 |
| Characterization and treatment of chronic active Epstein-Barr virus disease: a 28-year experience in the United States JI Cohen, ES Jaffe, JK Dale, S Pittaluga, HE Heslop, CM Rooney, ... Blood, The Journal of the American Society of Hematology 117 (22), 5835-5849, 2011 | 358 | 2011 |
| Complete responses of relapsed lymphoma following genetic modification of tumor-antigen presenting cells and T-lymphocyte transfer CM Bollard, S Gottschalk, AM Leen, H Weiss, KC Straathof, G Carrum, ... Blood, The Journal of the American Society of Hematology 110 (8), 2838-2845, 2007 | 342 | 2007 |
| Antitumor effects of chimeric receptor engineered human T cells directed to tumor stroma S Kakarla, KKH Chow, M Mata, DR Shaffer, XT Song, MF Wu, H Liu, ... Molecular Therapy 21 (8), 1611-1620, 2013 | 331 | 2013 |
| An Epstein-Barr virus deletion mutant associated with fatal lymphoproliferative disease unresponsive to therapy with virus-specific CTLs S Gottschalk, CYC Ng, M Perez, CA Smith, C Sample, MK Brenner, ... Blood, The Journal of the American Society of Hematology 97 (4), 835-843, 2001 | 320 | 2001 |
| Treatment of solid organ transplant recipients with autologous Epstein Barr virus–specific cytotoxic T lymphocytes (CTLs) B Savoldo, JA Goss, MM Hammer, L Zhang, T Lopez, AP Gee, YF Lin, ... Blood 108 (9), 2942-2949, 2006 | 304 | 2006 |
| Adoptive T-cell transfer and chemotherapy in the first-line treatment of metastatic and/or locally recurrent nasopharyngeal carcinoma WK Chia, M Teo, WW Wang, B Lee, SF Ang, WM Tai, CL Chee, J Ng, ... Molecular Therapy 22 (1), 132-139, 2014 | 286 | 2014 |
| Rapidly generated multivirus-specific cytotoxic T lymphocytes for the prophylaxis and treatment of viral infections U Gerdemann, JM Keirnan, UL Katari, R Yanagisawa, AS Christin, ... Molecular therapy 20 (8), 1622-1632, 2012 | 276 | 2012 |
| Transgenic expression of IL15 improves antiglioma activity of IL13Rα2-CAR T cells but results in antigen loss variants G Krenciute, BL Prinzing, Z Yi, MF Wu, H Liu, G Dotti, IV Balyasnikova, ... Cancer immunology research 5 (7), 571-581, 2017 | 272 | 2017 |
| T cells redirected to EphA2 for the immunotherapy of glioblastoma KKH Chow, S Naik, S Kakarla, VS Brawley, DR Shaffer, Z Yi, N Rainusso, ... Molecular Therapy 21 (3), 629-637, 2013 | 272 | 2013 |
Helen HeslopCenter for Cell and Gene Therapy, Baylor College of Medicine, Houston Methodist Hospital and Texas在 bcm.edu 的电子邮件经过验证
